PapersFlow Research Brief
Hemoglobinopathies and Related Disorders
Research Guide
What is Hemoglobinopathies and Related Disorders?
Hemoglobinopathies and related disorders are inherited blood disorders caused by mutations in globin genes that result in abnormal hemoglobin structure, reduced synthesis, or disrupted iron homeostasis, leading to conditions such as sickle cell disease, thalassemias, and anemias of chronic disease.
The field encompasses over 125,350 published works focused on genetic, biochemical, and therapeutic aspects of these disorders. Key historical advances include enzymatic amplification for diagnosing sickle cell anemia, as shown by Saiki et al. (1985), and hepcidin's role in iron regulation by Nemeth et al. (2004). Mortality data reveal that 50% of sickle cell anemia patients survive beyond the fifth decade, with early deaths often linked to acute pain episodes or stroke (Platt et al., 1994).
Research Sub-Topics
Sickle Cell Disease Pathophysiology
Investigates polymerization of HbS, vascular occlusion, hemolysis, and chronic organ damage mechanisms. Research uses patient cohorts, mouse models, and biophysical studies of red cell rheology.
Thalassemia Molecular Genetics and Modifiers
Studies α- and β-thalassemia mutations, globin switching, and genetic modifiers of clinical severity. Includes genotype-phenotype correlations and epigenetic regulation of globin genes.
Hemochromatosis HFE Gene and Iron Homeostasis
Elucidates HFE protein function in hepatocyte iron sensing, hepcidin regulation, and hereditary iron overload. Research spans population genetics, animal knockouts, and therapeutic phlebotomy optimization.
Anemia of Chronic Disease Hepcidin Regulation
Examines inflammatory cytokine effects on hepcidin-ferroportin axis causing functional iron deficiency. Studies IL-6 signaling, hypoxia responses, and therapeutic hepcidin modulation.
Gene Therapy for Beta-Hemoglobinopathies
Develops lentiviral vectors for fetal hemoglobin reactivation (BCL11A, LRF) and beta-globin correction using CRISPR/Cas9. Clinical trials assess engraftment, genotoxicity, and long-term efficacy.
Why It Matters
Hemoglobinopathies impose a substantial global health burden, affecting over 250,000 newborns annually with conditions like sickle cell disease and thalassemias, which cause vaso-occlusion, chronic anemia, organ damage, and increased stroke risk. Saiki et al. (1985) developed PCR-based restriction site analysis that amplified β-globin sequences 220,000-fold, enabling rapid prenatal diagnosis of sickle cell anemia and transforming genetic screening in high-prevalence regions. Nemeth et al. (2004) demonstrated that hepcidin binds ferroportin to regulate cellular iron efflux, explaining iron overload in hereditary hemochromatosis and anemia of inflammation, as reviewed by Weiß and Goodnough (2005). Recent approvals like Casgevy (CRISPR-based) by the NHS and BEAM-101 by the FDA address severe sickle cell disease through autologous stem cell editing, while high-precision base editing trials show sustained fetal hemoglobin increases. These interventions reduce transfusion dependence in β-thalassemia and compound hemoglobinopathies.
Reading Guide
Where to Start
"Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia" (Saiki et al., 1985) introduces PCR's transformative role in hemoglobinopathy diagnostics with 220,000-fold amplification, providing a foundational molecular entry point.
Key Papers Explained
Saiki et al. (1985) established PCR diagnostics for sickle cell anemia, building toward Platt et al. (1994), who quantified 50% survival past age 50 and acute mortality risks. Nemeth et al. (2004) connected iron regulation via hepcidin-ferroportin binding to disorders like hemochromatosis (Feder et al., 1996) and anemia of chronic disease (Weiß and Goodnough, 2005), linking genetics to pathophysiology.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on CRISPR/Cas9 trials for β-thalassemia and sickle cell, including base editing for fetal hemoglobin induction and machine learning diagnostics. NHS approval of Casgevy and FDA regenerative status for BEAM-101 highlight implementation challenges. Gene therapy for HbSC and compound states remains investigational.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Automatic Recording Apparatus for Use in Chromatography of Ami... | 1958 | Analytical Chemistry | 9.6K | ✕ |
| 2 | Enzymatic Amplification of β-Globin Genomic Sequences and Rest... | 1985 | Science | 9.0K | ✕ |
| 3 | Estimation of total, protein-bound, and nonprotein sulfhydryl ... | 1968 | Analytical Biochemistry | 7.9K | ✕ |
| 4 | Hepcidin Regulates Cellular Iron Efflux by Binding to Ferropor... | 2004 | Science | 4.7K | ✕ |
| 5 | A novel MHC class I–like gene is mutated in patients with here... | 1996 | Nature Genetics | 3.7K | ✕ |
| 6 | Anemia of Chronic Disease | 2005 | New England Journal of... | 3.7K | ✕ |
| 7 | Mortality In Sickle Cell Disease -- Life Expectancy and Risk F... | 1994 | New England Journal of... | 3.3K | ✓ |
| 8 | THE ESTIMATION OF PEPSIN, TRYPSIN, PAPAIN, AND CATHEPSIN WITH ... | 1938 | The Journal of General... | 3.3K | ✓ |
| 9 | Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease | 2006 | New England Journal of... | 2.7K | ✓ |
| 10 | Diabetes mellitus: a "thrifty" genotype rendered detrimental b... | 1999 | PubMed | 2.5K | ✓ |
In the News
NHS Approves Revolutionary CRISPR Gene Therapy ... - Helios
Funding for Casgevy will be provided through the Innovative Medicines Fund, a dedicated NHS initiative designed to facilitate patient access to cutting-edge treatments while gathering additional da...
Beam Therapeutics Announces U.S. FDA Regenerative ...
BEAM-101 is an investigational genetically modified cell therapy for the treatment of severe sickle cell disease (SCD). The one-time therapy consists of autologous CD34+ hematopoietic stem and prog...
Gene therapy for sickle cell disease: recent advances, clinical trials and future directions
* Previousarticlein issue * Nextarticlein issue ## Key Words Gene therapy lentiviral vectors CRISPR/Cas9 gene editing Fetal hemoglobin (HbF) induction Sickle cell disease Hemoglobinopathies Recomme...
High-Precision Base Editing Clinical Treatment for Sickle Cell ...
The breakthrough was achieved in an Investigator-Initiated Trial (IIT) conducted in collaboration with the First Affiliated Hospital of Guangxi Medical University. The patient demonstrated a signif...
Gene therapy for HbSC disease and other compound ...
Two gene therapy products have been approved by the US Food and Drug Administration for sickle cell disease. Nearly all patients in the clinical trials that led to approval either were sickle hemog...
Code & Tools
The code here is tailored specifically for HPCF at Stjude. It may not work directly outside Stjude. ## About HemTools: a collection of NGS pipeline...
This repository the terminology around heme comprising terms that are not belonging to any of the standard ontologies used in the biomedical domain...
This is the HDR UK National Phenotype Library that provides comprehensive, open-access resource providing the research community with information, ...
You can’t perform that action at this time.
# Search code, repositories, users, issues, pull requests... Search Clear Search syntax tips # Provide feedback We read every piece of feedba...
Recent Preprints
Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges - PubMed
Sickle cell disease (SCD) is a hereditary blood disorder caused by a specific mutation in the β-globin gene, leading to the production of hemoglobin S, which deforms red blood cells, causing occlus...
Crispr/Cas9 gene editing in transfusion-dependent β-thalassemia and sickle cell disease: a systematic review of non-randomized clinical trials
β-Thalassemia and sickle cell disease are the most common hereditary β-hemoglobinopathies. The current available treatments for their severe cases include frequent blood transfusions, iron chelatio...
Knowledge mapping and bibliometric insights into gene therapy for rare inherited hematologic pathologies: focus on sickle cell disease, hemophilia, and thalassemia
Inherited hematologic disorders such as sickle cell disease (SCD), thalassemia, and hemophilia are rare but devastating conditions with high morbidity and mortality. Advances in gene therapy have o...
Accurate diagnosis of hemoglobinopathies with machine ...
Hemoglobinopathies, such as sickle cell disease and thalassemias, impose a substantial global burden, particularly in endemic regions. Current diagnostic methods, such as high‐performance liquid ch...
Advances in Hemoglobinopathies: From Molecular Insights ...
Hemoglobinopathies, such as thalassemia and sickle cell anemia, are among the most common genetic disorders worldwide, impacting more than 250,000 newborns annually. These inherited conditions aris...
Latest Developments
Recent developments in hemoglobinopathies and related disorders research include FDA-approved gene therapies such as Lyfgenia for sickle cell disease in 2023, the approval of a world-first gene-editing treatment for sickle cell disease by NICE in 2025, and ongoing trials of gene therapies like exagamglogene autotemcel (exa-cel) showing improved quality of life for patients with sickle cell disease and beta thalassemia as of 2025 (mdpi.com, imperial.nhs.uk, hematology.org, nejm.org). Additionally, innovative approaches such as base editing to boost hemoglobin levels and research into the mechanisms of fetal-to-adult hemoglobin switching are actively advancing the field (nature.com, nature.com).
Sources
Frequently Asked Questions
What is the role of hepcidin in hemoglobinopathies?
Hepcidin, secreted by the liver, binds ferroportin to induce its internalization and block cellular iron efflux. Decreased hepcidin causes tissue iron overload, while excess leads to hypoferremia and anemia of inflammation (Nemeth et al., 2004). Ferroportin is expressed on absorptive enterocytes, macrophages, and hepatocytes.
How is sickle cell anemia diagnosed using molecular methods?
Primer-mediated enzymatic amplification of β-globin sequences achieves a 220,000-fold increase in target DNA, followed by restriction site analysis to detect the sickle cell mutation. This method provides rapid, sensitive prenatal diagnosis (Saiki et al., 1985). It targets specific genomic regions for accurate genotyping.
What are mortality risks in sickle cell disease?
Fifty percent of patients with sickle cell anemia survive beyond age 50, but many deaths occur during acute pain, chest syndrome, or stroke without chronic organ failure. Early mortality is highest in symptomatic cases (Platt et al., 1994). Risk factors include disease severity indicators.
What causes anemia of chronic disease?
Disturbances in iron homeostasis, impaired erythroid progenitor proliferation, and reduced erythropoietin response contribute to anemia of chronic disease. New therapies target these mechanisms (Weiß and Goodnough, 2005). Inflammation elevates hepcidin, trapping iron in macrophages.
How does gene therapy address β-thalassemia and sickle cell disease?
CRISPR/Cas9 editing and lentiviral vectors induce fetal hemoglobin or correct β-globin mutations in hematopoietic stem cells. Treatments like Casgevy reduce transfusion needs in clinical trials for transfusion-dependent cases. Challenges include access and long-term efficacy (recent preprints).
Open Research Questions
- ? How can CRISPR/Cas9 editing achieve durable, transfusion-free outcomes in diverse β-hemoglobinopathy genotypes beyond homozygous sickle cell?
- ? What access barriers limit clinical implementation of gene therapies like BEAM-101 and Casgevy in endemic regions?
- ? How do hepcidin-ferroportin interactions differ in hereditary hemochromatosis versus inflammation-driven anemias?
- ? Which molecular variants evade current HPLC and electrophoresis diagnostics for hemoglobinopathies?
- ? What long-term risks arise from fetal hemoglobin induction in gene-edited sickle cell patients?
Recent Trends
Gene therapy dominates with CRISPR/Cas9 trials for sickle cell disease and β-thalassemia, as in "Crispr/Cas9 gene editing in transfusion-dependent β-thalassemia and sickle cell disease" and NHS Casgevy approval.
2025BEAM-101 receives FDA regenerative status for severe SCD.
2025-08-14High-precision base editing yields sustained fetal hemoglobin in trials , shifting from diagnostics to curative autologous editing amid 125,350 works.
2025-08-26Research Hemoglobinopathies and Related Disorders with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Hemoglobinopathies and Related Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.